Tyra Biosciences (NASDAQ:TYRA) Price Target Increased to $33.00 by Analysts at Oppenheimer

Tyra Biosciences (NASDAQ:TYRA) had its price objective boosted by Oppenheimer from $25.00 to $33.00 in a report issued on Thursday, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

A number of other equities analysts have also recently weighed in on TYRA. Wedbush reissued an outperform rating and set a $28.00 price target on shares of Tyra Biosciences in a research report on Thursday, August 8th. HC Wainwright reissued a buy rating and issued a $23.00 target price on shares of Tyra Biosciences in a research note on Wednesday, July 3rd. Finally, Piper Sandler began coverage on Tyra Biosciences in a report on Thursday, August 15th. They issued an overweight rating and a $33.00 price target for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus price target of $26.40.

Tyra Biosciences Trading Up 3.4 %

NASDAQ:TYRA opened at $23.99 on Thursday. Tyra Biosciences has a 1-year low of $10.38 and a 1-year high of $25.14. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of -14.28 and a beta of 1.01. The business’s 50-day moving average price is $21.20 and its two-hundred day moving average price is $18.70.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.09. Sell-side analysts predict that Tyra Biosciences will post -1.53 earnings per share for the current year.

Hedge Funds Weigh In On Tyra Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its stake in shares of Tyra Biosciences by 12.3% in the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after purchasing an additional 2,574 shares during the period. Wellington Management Group LLP raised its position in Tyra Biosciences by 8.8% in the 4th quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock valued at $1,419,000 after buying an additional 8,324 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Tyra Biosciences by 32.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock valued at $929,000 after acquiring an additional 14,352 shares in the last quarter. HighVista Strategies LLC acquired a new position in Tyra Biosciences during the 2nd quarter worth approximately $257,000. Finally, Victory Capital Management Inc. grew its stake in shares of Tyra Biosciences by 53.4% during the 4th quarter. Victory Capital Management Inc. now owns 50,220 shares of the company’s stock worth $696,000 after acquiring an additional 17,490 shares in the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.